tazemetostat
Selected indexed studies
- Tazemetostat. (, 2012) [PMID:37643279]
- Tazemetostat: First Approval. (Drugs, 2020) [PMID:32166598]
- Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. (Lancet Oncol, 2020) [PMID:33035459]
_Worker-drafted node — pending editorial review._
Connections
tazemetostat is a side effect of
Sources
- Tazemetostat. (2012) pubmed
- Tazemetostat: First Approval. (2020) pubmed
- Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. (2020) pubmed
- Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. (2023) pubmed
- Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. (2020) pubmed
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. (2018) pubmed
- Pharmacology and pharmacokinetics of tazemetostat. (2024) pubmed
- Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives. (2021) pubmed
- Tazemetostat: EZH2 Inhibitor. (2022) pubmed
- Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors. (2023) pubmed